Historical Valuation
BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.45 is considered Undervalued compared with the five-year average of 39.39. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 70.94 to 242.43 according to relative valuation methord. Compared to the current price of 58.95 USD , BioMarin Pharmaceutical Inc is Undervalued By 16.9%.
Relative Value
Fair Zone
70.94-242.43
Current Price：58.95
16.9%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BioMarin Pharmaceutical Inc (BMRN) has a current Price-to-Book (P/B) ratio of 1.89. Compared to its 3-year average P/B ratio of 2.88 , the current P/B ratio is approximately -34.43% higher. Relative to its 5-year average P/B ratio of 3.16, the current P/B ratio is about -40.25% higher. BioMarin Pharmaceutical Inc (BMRN) has a Forward Free Cash Flow (FCF) yield of approximately 7.29%. Compared to its 3-year average FCF yield of 2.43%, the current FCF yield is approximately 199.79% lower. Relative to its 5-year average FCF yield of 1.71% , the current FCF yield is about 325.70% lower.
P/B
Median3y
2.88
Median5y
3.16
FCF Yield
Median3y
2.43
Median5y
1.71
Competitors Valuation Multiple
AI Analysis for BMRN
The average P/S ratio for BMRN competitors is 190.44, providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN.O) exhibits a P/S ratio of 3.39, which is -98.22% above the industry average. Given its robust revenue growth of 4.08%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BMRN
1Y
3Y
5Y
Market capitalization of BMRN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BMRN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BMRN currently overvalued or undervalued?
BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.45 is considered Undervalued compared with the five-year average of 39.39. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 70.94 to 242.43 according to relative valuation methord. Compared to the current price of 58.95 USD , BioMarin Pharmaceutical Inc is Undervalued By 16.90% .
What is BioMarin Pharmaceutical Inc (BMRN) fair value?
BMRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 70.94 to 242.43 according to relative valuation methord.
How does BMRN's valuation metrics compare to the industry average?
The average P/S ratio for BMRN's competitors is 190.44, providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN) exhibits a P/S ratio of 3.39, which is -98.22% above the industry average. Given its robust revenue growth of 4.08%, this premium appears unsustainable.
What is the current P/B ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jan 10 2026?
As of Jan 10 2026, BioMarin Pharmaceutical Inc (BMRN) has a P/B ratio of 1.89. This indicates that the market values BMRN at 1.89 times its book value.
What is the current FCF Yield for BioMarin Pharmaceutical Inc (BMRN) as of Jan 10 2026?
As of Jan 10 2026, BioMarin Pharmaceutical Inc (BMRN) has a FCF Yield of 7.29%. This means that for every dollar of BioMarin Pharmaceutical Inc’s market capitalization, the company generates 7.29 cents in free cash flow.
What is the current Forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jan 10 2026?
As of Jan 10 2026, BioMarin Pharmaceutical Inc (BMRN) has a Forward P/E ratio of 13.45. This means the market is willing to pay $13.45 for every dollar of BioMarin Pharmaceutical Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jan 10 2026?
As of Jan 10 2026, BioMarin Pharmaceutical Inc (BMRN) has a Forward P/S ratio of 3.39. This means the market is valuing BMRN at $3.39 for every dollar of expected revenue over the next 12 months.